COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,889 Articles (22,568 medRxiv, 8,321 bioRxiv)

Most recent first Previous |  Page 214: Articles 2131-2140  | Next

Determining the feasibility of linked claims and vaccination data for a Covid-vaccine pharmaco-epidemiological study in Germany - RiCO feasibility study protocol
Timmesfeld, N., Ihle, P., Denz, R., Meiszl, K., Scholz, K., Oberle, D., Drechsel-Baeuerle, U., Keller-Stanislawski, B., Diebner, H. H., Meyer, I.
10.1101/2024.03.04.24303714 — Posted: 2024-03-04
Modelling long COVID using Bayesian networks
Perez Chacon, G., Mascaro, S., Estcourt, M. J., Phetsouphanh, C., Nicholson, A. E., Snelling, T., Wu, Y.
10.1101/2024.03.04.24303715 — Posted: 2024-03-04
Genome-wide association study between SARS-CoV-2 single nucleotide polymorphisms and virus copies during infections
Li, K., Chaguza, C., Chew, Y. T., Chen, N. F. G., Ferguson, D., Pandya, S., Kerantzas, N., Schulz, W., Yale SARS-CoV-2 Genomic Surveillance Initiative, , Hahn, A. M., Pitzer, V. E., Weinberger, D. M., Grubaugh, N. D.
10.1101/2024.03.02.24303655 — Posted: 2024-03-04
The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: a cross sectional study
Koirala, A., McRae, J., Britton, P. N., Downes, M., Prasad, S. A., Nicholson, S., Winkler, N. E., O'Sullivan, M., Gondalwala, F., Castellano, C., Carey, E., Hendry, A., Crawford, N., Wadia, U. D., Richmond, P., Marshall, H. S., Clark, J. E., Francis, J. R., Carr, J., Bartlett, A., McMullan, B., Skowno, J., Hannah, D., Davidson, A., von Ungern-Sternbeg, B. S., Lee-Archer, P., Burgoyne, L. L.-a., Waugh, E. B., Carlin, J. B., Naing, Z., Kerly, N., McMinn, A., Hunter, G., Heath, C., D'Angelo, N., Finucane, C., Francis, L. A., Dougherty, S., Rawlinson, W., Karapanagiotidis, T., Cain, N., Brizuela
10.1101/2024.03.03.24303672 — Posted: 2024-03-04
Engineering customized viral receptors for various coronaviruses
Liu, P., Huang, M., Guo, H., Si, J., Chen, Y., Wang, C., Yu, X., Shi, L., Xiong, Q., Ma, C., Tong, F., Liu, C., Chen, J., Guo, M., Li, J., Shi, Z.-L., Yan, H.
10.1101/2024.03.03.583237 — Posted: 2024-03-04
Immunogenicity and safety of a live-attenuated SARS-CoV-2 vaccine candidate based on multiple attenuation mechanisms
Suzuki, M., Okamura, S., Gis, T., Sasaki, H., Lee, S., Yoshida, A., Goto, S., Nakagawa, T., Ikawa, M., Kamitani, W., Takekawa, S., Yamanishi, K., Ebina, H.
10.1101/2024.03.03.582873 — Posted: 2024-03-04
Heterogeneous hybrid immunity against Omicron variant JN.1 at 11 months following breakthrough infection
He, X., Jiang, J., Li, G., Liu, J., Gan, J., Zhou, L., Bai, C., Zi, Q., Mou, X., Zeng, S., Yuan, J., Zhou, C., Li, Y., Zhu, G., Zhao, R., Yang, L., Wu, J., Zhang, H., Xian, J., Wang, Z., Qi, Q., Liu, Y., Yu, J., Liu, D., Li, W.
10.1101/2024.03.02.583082 — Posted: 2024-03-04
Physics-driven structural docking and protein language models accelerate antibody screening and design for broad-spectrum antiviral therapy
Mubarak, H. F., Tan, W., Hoffmann, A. D., Wei, J., El-Shennawy, L., Squires, J. R., Sun, Y., Dashzeveg, N. K., Simonton, B., Jia, Y., Iyer, R., Xu, Y., Nicolaescu, V., Elli, D., Randall, G. C., Schipma, M. J., Swaminathan, S., Ison, M. G., Liu, H., Fang, D., Shen, Y.
10.1101/2024.03.01.582176 — Posted: 2024-03-04
Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate AVX/COVID-12 Activates T Cells and Is Recognized by Antibodies from COVID-19 Patients and Vaccinated
Torres-Flores, A., Ontiveros-Padilla, L. A., Madera-Sandoval, R. L., Tepale-Segura, A., Gajon-Martinez, J., Rivera-Hernandez, T., Ferat-Osorio, E. A., Cerbulo-Vazquez, A., Arriaga-Pizano, L. A., Bonifaz, L., Paz-De la Rosa, G., Rojas-Martinez, O., Suarez-Martinez, A., Peralta-Sanchez, G., Sarfati-Mizrahi, D., Sun, W., Chagoya-Cortes, H. E., Palese, P., Krammer, F., Garcia-Sastre, A., Lozano-Dubernard, B., Lopez-Macias, C.
10.1101/2024.03.01.582987 — Posted: 2024-03-04
B cell maturation restored ancestral germlines to control Omicron BA.2.86
Paciello, I., Pierleoni, G., Pantano, E., Antonelli, G., Pileri, P., Maccari, G., Cardamone, D., Realini, G., Perrone, F., Neto, M. M., Pozzessere, S., Fabbiani, M., Panza, F., Rancan, I., Tumbarello, M., Montagnani, F., Medini, D., Maes, P., Temperton, N. J., Simon-Loriere, E., Schwartz, O., Rappuoli, R., Andreano, E.
10.1101/2024.03.03.583187 — Posted: 2024-03-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).